Related references
Note: Only part of the references are listed.Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma
Robin K. Kelley et al.
ADVANCES IN THERAPY (2020)
Navigating the new landscape of second-line treatment in advanced hepatocellular carcinoma
Lorenza Rimassa et al.
LIVER INTERNATIONAL (2020)
Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trials
Andrew X. Zhu et al.
ESMO OPEN (2020)
Comparing the efficacy and safety of second-line therapies for advanced hepatocellular carcinoma: a network meta-analysis of phase III trials
Dongxu Wang et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2020)
Quality-adjusted life years assessment using cabozantinib for patients with advanced hepatocellular carcinoma (aHCC) in the CELESTIAL trial.
Ghassan K. Abou-Alfa et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Association of adverse events (AEs) with efficacy outcomes for cabozantinib (C) in patients (pts) with advanced hepatocellular carcinoma (aHCC) in the phase III CELESTIAL trial.
Ghassan K. Abou-Alfa et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Peter R. Galle et al.
JOURNAL OF HEPATOLOGY (2018)
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
G. K. Abou-Alfa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
A. Vogel et al.
ANNALS OF ONCOLOGY (2018)
The prognostic correlation of AFP level at diagnosis with pathological grade, progression, and survival of patients with hepatocellular carcinoma
Dou-Sheng Bai et al.
SCIENTIFIC REPORTS (2017)
Diagnostics for the Cox model
Yishu Xue et al.
COMMUNICATIONS FOR STATISTICAL APPLICATIONS AND METHODS (2017)
MATCHING ADJUSTED INDIRECT COMPARISONS TO ASSESS COMPARATIVE EFFECTIVENESS OF THERAPIES: USAGE IN SCIENTIFIC LITERATURE AND HEALTH TECHNOLOGY APPRAISALS
H. Thom et al.
VALUE IN HEALTH (2016)
Matching-Adjusted Indirect Comparisons: A New Tool for Timely Comparative Effectiveness Research
James E. Signorovitch et al.
VALUE IN HEALTH (2012)
Comparative Effectiveness Without Head-to-Head Trials A Method for Matching-Adjusted Indirect Comparisons Applied to Psoriasis Treatment with Adalimumab or Etanercept
James E. Signorovitch et al.
PHARMACOECONOMICS (2010)
Share Paper
